Dr. Weiner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-353-8620Fax+1 319-353-8988
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 1985 - 1989
University of ToledoResidency, Internal Medicine, 1981 - 1985
Ohio State University College of MedicineClass of 1981
Certifications & Licensure
IA State Medical License 1989 - 2026
MI State Medical License 1987 - 1991
OH State Medical License 1984 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Clinical Trials
- Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2004 Oct 01
- Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Jul 01
Publications & Presentations
PubMed
- 1 citationsMonocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to VidutolimodShakoora A Sabree, Caitlin D Lemke-Miltner, Sue E. Blackwell, Chaobo Yin, Aaron D. Bossler
Vaccines. 2021-09-02 - 67 citationsOvercoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez
Cancer Discovery. 2021-07-29 - 36 citationsIn situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapyYinwen Cheng, Caitlin D Lemke-Miltner, Wattawan Wongpattaraworakul, Zhaoming Wang, Carlos H. F. Chan
Journal for Immunotherapy of Cancer. 2020-10-01
Press Mentions
Bleeding HeartlandMarch 6th, 2023- Iowa Governor Sides with Anti-Vaxxers, Not Cancer ExpertsMarch 6th, 2023
- Iowa’s Cancer Battle: More People Are SurvivingMarch 1st, 2023
- Join now to see all
Grant Support
- Tumor ImagingNational Cancer Institute2011–2012
- Staff InvestigatorsNational Cancer Institute2011–2012
- Shared Resources - Tissue ProcurementNational Cancer Institute2011–2012
- Shared Resources - Small Animal ImagingNational Cancer Institute2011–2012
- Shared Resources - Gene Transfer Vector CoreNational Cancer Institute2011–2012
- Shared Resources - Flow Cytrometry CoreNational Cancer Institute2011–2012
- Shared Resources - DNA CoreNational Cancer Institute2011–2012
- Shared Resources - Central Microscopy Research FacilityNational Cancer Institute2011–2012
- Shared Resources - BioinformaticsNational Cancer Institute2011–2012
- Shared Resources - Radiation And Free Radical Research CoreNational Cancer Institute2011–2012
- Protocol Specific Research SupportNational Cancer Institute2011–2012
- Protocol Review Monitoring CommitteeNational Cancer Institute2011–2012
- Program Signaling And Experimental TherapeuticsNational Cancer Institute2011–2012
- Population Research CoreNational Cancer Institute2011–2012
- Free Radical Cancer BiologyNational Cancer Institute2011–2012
- Data And Safety MonitoringNational Cancer Institute2011–2012
- Clinical Trials Support CoreNational Cancer Institute2011–2012
- Cancer Immunology And ImmunotherapyNational Cancer Institute2011–2012
- Cancer Genomics And Cell GrowthNational Cancer Institute2011–2012
- Cancer EpidemiologyNational Cancer Institute2011–2012
- BiostatisticsNational Cancer Institute2011–2012
- AdministrationNational Cancer Institute2011–2012
- Planning And EvaluationNational Cancer Institute2009–2012
- Senior LeadershipNational Cancer Institute2005–2012
- Developmental FundsNational Cancer Institute2005–2012
- Cancer Center Support Grant (CCSG)National Cancer Institute2000–2012
- P1 - A Novel Approach To The Immunotherapy Of B Cell MalignancyNational Cancer Institute2010–2011
- Monoclonal Antibody-Induced NK Cell Activation And ComplementNational Cancer Institute2009–2011
- Lymphoma Specialized Program Of Research Excellence (SPORE)National Cancer Institute2007–2011
- Administrative CoreNational Cancer Institute2009
- A Novel Approach To The Immunotherapy Of B Cell MalignancyNational Cancer Institute2007–2009
- AdministrationNational Cancer Institute2007
- CPG ODN As An Immune AdjuvantNational Cancer Institute2003–2006
- Lymphoma Specialized Program Of Research ExcellenceNational Cancer Institute2002–2006
- Planning &EvaluationNational Cancer Institute2005
- Institutional National Research Service Award (T32)National Cancer Institute2000–2004
- Mechanism Of Action Of Anti-Hla-Dr AntibodyNational Cancer Institute2002
- Hum195 For Refractory Or Relapsed Acute Myelogenous LeukemiaNational Center For Research Resources1999–2002
- CPG ODN As An Adjuvant In Tumor ImmunizationNational Cancer Institute1999–2001
- Hum195 Maintenance Therapy In Elderly Patients With Acute Myelogenous LeukemiaNational Center For Research Resources1997–2000
- Bispecific Antibody Therapy Of B Cell LymphomaNational Cancer Institute1997–2000
- Anticd20 Mediated Signaling And Antitumor ResponseNational Cancer Institute1997–1998
- Bispecific Antibody Therapy Of B-Cell LymphomaNational Cancer Institute1992–1996
- Bispecific Antibody Therapy Of B-Cell LymphomaNational Cancer Institute1991
- ImmunologyNational Cancer Institute1989
- Antibody-Armed Effector Cell Therapy Of B-Cell LymphomaNational Cancer Institute1988
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
